This HTML5 document contains 28 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00011/identifier/uniprotkb/
n17http://linked.opendata.cz/resource/mesh/concept/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00011/identifier/genbank/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00011/identifier/pharmgkb/
n14http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n5http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00011/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00011
rdf:type
n3:Drug
n3:description
Purified, natural (n is for natural) glycosylated human interferon alpha proteins 166 residues
n3:group
approved
n3:halfLife
1.2 hours (mammalian reticulocytes, in vitro); >20 hours (yeast, in vivo); >10 hours (Escherichia coli, in vivo).
n3:indication
For treatment of venereal or genital warts caused by the Human Papiloma Virus
owl:sameAs
n5:DB00011 n14:DB00011
dcterms:title
Interferon alfa-n1
adms:identifier
n9:DB00011 n12:P01563 n13:PA164746538 n15:J00207
n3:mechanismOfAction
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
n3:synonym
Interferon alpha-A Interferon alpha-2 LeIF A
n3:foodInteraction
Avoid alcohol.
n3:synthesisReference
Vladimir G. Debabov, Jury D. Tsygankov, Andrei J. Chistoserdov, Evgeny D. Sverdlov, Lara S. Izotova, Sergei V. Kostrov, Viktor E. Sterkin, Vladimir P. Kuznetsov, Sergei V. Belyaev, Galina S. Monastyrskaya, Irina S. Salomatina, Grigory M. Dolganov, Sergei G. Arsenian, Sergei A. Tsarev, Jury I. Kozlov, Alexandr Y. Strongin, Vsevolod I. Ogarkov, Jury A. Ovchinnikov, "Method for producing human leukocyte interferon alpha-2." U.S. Patent US4680260, issued January, 1982.
n16:hasConcept
n17:M0025713
n3:Molecular-Formula
n6:271B3F0B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B3F0A-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:L03AB06
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
74899-72-2
n3:category
n3:Hydrophobicity
n6:271B3F08-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n6:271B3F09-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B3F07-363D-11E5-9242-09173F13E4C5